TY - JOUR
T1 - HIV epidemic trend and antiretroviral treatment need in Karonga District, Malawi
AU - White, Richard G.
AU - Vynnycky, E.
AU - Glynn, J. R.
AU - Crampin, A. C.
AU - Jahn, A.
AU - Mwaungulu, F.
AU - Mwanyongo, O.
AU - Jabu, H.
AU - Phiri, H.
AU - Mcgrath, N.
AU - Zaba, B.
AU - Fine, P. E.M.
PY - 2007/8
Y1 - 2007/8
N2 - We describe the development of the HIV epidemic in Karonga District, Malawi over 22 years using data from population surveys and community samples. These data are used to estimate the trend in HIV prevalence, incidence and need for antiretroviral treatment (ART) using a simple mathematical model. HIV prevalence rose quickly in the late 1980s and early 1990s, stabilizing at around 12% in the mid-1990s. Estimated annual HIV incidence rose quickly, peaking in the early 1990s at 2.2% among males and 3.1% among females, and then levelled off at 1.3% among males and 1.1% among females by the late 1990s. Assuming a 2-year eligibility period, both our model and the UNAIDS models predicted 2.1% of adults were in need of ART in 2005. This prediction was sensitive to the assumed eligibility period, ranging from 1.6% to 2.6% if the eligibility period was instead assumed to be 1.5 or 2.5 years, respectively.
AB - We describe the development of the HIV epidemic in Karonga District, Malawi over 22 years using data from population surveys and community samples. These data are used to estimate the trend in HIV prevalence, incidence and need for antiretroviral treatment (ART) using a simple mathematical model. HIV prevalence rose quickly in the late 1980s and early 1990s, stabilizing at around 12% in the mid-1990s. Estimated annual HIV incidence rose quickly, peaking in the early 1990s at 2.2% among males and 3.1% among females, and then levelled off at 1.3% among males and 1.1% among females by the late 1990s. Assuming a 2-year eligibility period, both our model and the UNAIDS models predicted 2.1% of adults were in need of ART in 2005. This prediction was sensitive to the assumed eligibility period, ranging from 1.6% to 2.6% if the eligibility period was instead assumed to be 1.5 or 2.5 years, respectively.
UR - http://www.scopus.com/inward/record.url?scp=34248516563&partnerID=8YFLogxK
U2 - 10.1017/S0950268806007680
DO - 10.1017/S0950268806007680
M3 - Article
C2 - 17217548
AN - SCOPUS:34248516563
SN - 0950-2688
VL - 135
SP - 922
EP - 932
JO - Epidemiology and Infection
JF - Epidemiology and Infection
IS - 6
ER -
